ArticleEndocrine2025
Clinical characteristics and survival of patients with calcitonin-secreting neuroendocrine neoplasms: experience from a series of 71 patients.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough calcitonin (CT)-secreting neuroendocrine neoplasms (NENs) represent a relevant differential diagnosis for medullary thyroid carcinoma, the paucity of data makes it difficult to define their prevalence and biology. The purpose of this study was to evaluate important clinical features of CT-secreting NENs.
methodsWe retrospectively analysed all CT-secreting NENs in a series of 1216 patients with NENs of all primary locations treated at a national referral centre over a course of 20 years. We performed necessary laboratory, histopathological, morphological and functional work-up. Statistical analysis was performed with SPSS, with a p value ≤ 0.05 considered as significant.
resultsWe identified 71 patients with CT-secreting NENs that predominantly originated from the pancreas and lung. The majority of tumours were of a higher grade and were mostly metastatic (91.5%). Almost one-third of the tumours (32.4%) co-secreted another hormone(s). Diarrhoea was rarely present (21.1%) and was not correlated with CT values (p = 0.174). The calcitonin level did not correlate with the Ki67 index but was correlated with the presence of metastatic disease (p = 0.008). The median overall survival was 15.0 ± 4.7 months (95% CI 5.8–24.2). A total of 64.8% of patients had CT values above 100 pg/mL. Although this group had significantly shorter survival (p = 0.048), this was proven to be the effect of more frequent metastatic disease.
conclusionCalcitonin secretion seems to be a marker of more aggressive tumour behaviour. We suggest that CT measurements should be more systematic, at least for pancreatic and lung NENs.
Indexed as
Identifiers
41014428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.